|
rdf:type |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
1991-8-8
|
|
pubmed:abstractText |
There were synthesized new hemosorbents for selective removal of LDL, based on macroporous silica, immobilised by heparine (sorbent 1) and chytozane-sulphate (sorbent 2). Experimental data showed satisfactory hemo- and biocompatibility of the new sorbents. No significant alterations in biochemical parameters were observed. Sorption cholesterol (Ch) capacity of the sorbents was equal and accounted for 15 mg of Ch per 1 g of the sorbent. Pilot clinical studies in familial hypercholesterolemia (FH) patients have shown the satisfactory hemo- and biocompatibility of the sorbent 1, and its significant Ch withdrawal. We conclude that the hemosorbents can be used in the FH patients treatment.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0890-5533
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
18
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
571-8
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:1965948-Adult,
pubmed-meshheading:1965948-Animals,
pubmed-meshheading:1965948-Biocompatible Materials,
pubmed-meshheading:1965948-Blood Pressure,
pubmed-meshheading:1965948-Cholesterol, HDL,
pubmed-meshheading:1965948-Cholesterol, LDL,
pubmed-meshheading:1965948-Cholesterol, VLDL,
pubmed-meshheading:1965948-Diet, Atherogenic,
pubmed-meshheading:1965948-Hemoperfusion,
pubmed-meshheading:1965948-Humans,
pubmed-meshheading:1965948-Hyperlipoproteinemia Type II,
pubmed-meshheading:1965948-Materials Testing,
pubmed-meshheading:1965948-Rabbits,
pubmed-meshheading:1965948-Silicon Dioxide
|
|
pubmed:year |
1990
|
|
pubmed:articleTitle |
LDL-apheresis on affine haemosorbents.
|
|
pubmed:affiliation |
Research Institute of Physico-Chemical Medicine, Moscow, USSR.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study
|
